Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride Camera (DaTBase)

July 17, 2025 updated by: Antoine VERGER, Central Hospital, Nancy, France

Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride (CZT) Camera (VERITON-CT)

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

There are several types of cameras allowing its performance:

  • Conventional Anger cameras and,
  • CZT (Cadmium-Zinc-Telluride) semiconductor cameras. At the Nancy University Hospital, the nuclear medicine department has a wide-field Cadmium-Zinc-Telluride camera: VERITON-CT (Spectrum Dynamics). The interpretation of this examination is purely visual.

The objectives are therefore to:

  • Create the first international database of semi-quantitative values in 3D scintigraphy with Datscan performed with a VERITON-CT camera.
  • Compare this database with another database from a conventional Anger camera (Lyon Nuclear Medicine Department) to show its superiority.

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Adult patients who have undergone a Datscan® scintigraphy on the VERITON-CT camera in the nuclear medicine department of the Nancy University Hospital and who have an established clinical diagnosis, in the absence of neurodegenerative pathology or Parkinson's disease or Lewy body disease

Description

Inclusion Criteria:

  • Adult patients who have undergone a Datscan scintigraphy on the VERITON camera in the nuclear medicine department of the Nancy University Hospital and who have an established clinical diagnosis, -Absence of neurodegenerative pathology or Parkinson's disease or Lewy body disease.
  • The clinical diagnosis can only be established after two years of clinical follow-up.

Exclusion Criteria:

  • Excluded from this research will be the patients opposed to the use of their data, minors, atypical Parkinsonian syndromes,
  • patients who died before two years of clinical follow-up,
  • patients who had their Datscan examination carried out on a camera other than the VERITON and - patients lost to follow-up.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To create the first international database of Datscan by camera VERITON-CT.
Time Frame: One day
Fixation ratio of central gray nuclei of the brain namely, the global striatum, caudate nuclei, putamens
One day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Compare this database with another database from another type of camera (Lyon nuclear medicine team) to show its superiority.
Time Frame: One day
Identical to the primary evaluation criterion compared to those of the Lyon database.
One day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central Hospital, Nancy, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 30, 2025

Primary Completion (Estimated)

August 15, 2025

Study Completion (Estimated)

November 30, 2025

Study Registration Dates

First Submitted

January 31, 2025

First Submitted That Met QC Criteria

February 11, 2025

First Posted (Actual)

February 14, 2025

Study Record Updates

Last Update Posted (Actual)

July 22, 2025

Last Update Submitted That Met QC Criteria

July 17, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024PI206

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurodegenerative Diseases

Clinical Trials on datscan scintigraphy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe